Advertisement

Ovarian cancer prognosis in women with endometriosis: a retrospective nationwide cohort study of 32,419 women

Published:August 21, 2020DOI:https://doi.org/10.1016/j.ajog.2020.08.056

      Background

      Contradicting results regarding ovarian cancer prognosis in women with endometriosis have been reported in the literature. Owing to the small sample size of previous studies, larger studies are required to elucidate the role of endometriosis in ovarian cancer prognosis.

      Objective

      This study aimed to evaluate the survival rate in women with ovarian cancer with or without histologically proven endometriosis in a Dutch population-based cohort.

      Study Design

      All women with ovarian cancer diagnosed between 1990 and 2015 were identified from the Netherlands Cancer Registry. We linked these women with the Dutch nationwide registry of histopathology and cytopathology (Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief) to identify all women with histologically proven endometriosis. We compared the prognosis of patients with ovarian cancer with and without histologically proven endometriosis. Primary outcome was the overall survival with subgroup analyses stratified by histologic ovarian cancer subtype and stage. Multivariable Cox proportional hazard analysis was used to estimate hazard ratios with 95% confidence intervals.

      Results

      We included 32,419 patients with ovarian cancer, of whom 1979 (6.1%) had histologically proven endometriosis. The median age of histologic endometriosis diagnosis was 53 years (interquartile range, 46–62). Of all women with ovarian cancer and endometriosis, 81.2% received a diagnosis of synchronous endometriosis and ovarian cancer. The endometriosis cohort was younger at ovarian cancer diagnosis, had more favorable tumor characteristics, and more often had surgical treatment for ovarian cancer than the women without endometriosis. These variables were included in the multivariable model as confounders. Women with histologically proven endometriosis had a significantly better prognosis in both crude and adjusted analyses (hazard ratio, 0.46; 95% confidence interval, 0.43–0.49; P<.0005, and adjusted hazard ratio, 0.89; 95% confidence interval, 0.83–0.95; P<.05, respectively).

      Conclusion

      Women with ovarian cancer and histologically proven endometriosis had longer overall survival than women with ovarian cancer without endometriosis, even after adjustment for confounders. Future studies on ovarian cancer treatment and prognosis should consider stratifying by endometriosis status to elucidate its role. Furthermore, women diagnosed as having ovarian cancer and concurrent endometriosis should be explained the role of endometriosis in ovarian cancer survival.

      Key words

      To read this article in full you will need to make a payment

      References

        • Adamson G.D.
        • Kennedy S.H.
        • Hummelshoj L.
        Creating solutions in endometriosis: global collaboration through the World Endometriosis Research Foundation.
        J Endometriosis. 2010; 2: 3-6
        • Dunselman G.A.
        • Vermeulen N.
        • Becker C.
        • et al.
        ESHRE guideline: management of women with endometriosis.
        Hum Reprod. 2014; 29: 400-412
        • Sampson J.A.
        Endometrial carcinoma of the ovary, arising in endometrial tissue in that organ.
        Arch Surg. 1925; 10: 1-72
        • Hermens M.
        • van Altena A.M.
        • Nieboer T.E.
        • et al.
        Incidence of endometrioid and clear-cell ovarian cancer in histological proven endometriosis: the ENOCA population-based cohort study.
        Am J Obstet Gynecol. 2020; 223: 107.e1-107.e11
        • Pearce C.L.
        • Templeman C.
        • Rossing M.A.
        • et al.
        Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.
        Lancet Oncol. 2012; 13: 385-394
        • Buis C.C.
        • van Leeuwen F.E.
        • Mooij T.M.
        • Burger C.W.
        • OMEGA Project Group
        Increased risk for ovarian cancer and borderline ovarian tumours in subfertile women with endometriosis.
        Hum Reprod. 2013; 28: 3358-3369
        • Poole E.M.
        • Lin W.T.
        • Kvaskoff M.
        • De Vivo I.
        • Terry K.L.
        • Missmer S.A.
        Endometriosis and risk of ovarian and endometrial cancers in a large prospective cohort of U.S. nurses.
        Cancer Causes Control. 2017; 28: 437-445
        • Ferlay J.
        • Colombet M.
        • Soerjomataram I.
        • et al.
        Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018.
        Eur J Cancer. 2018; 103: 356-387
        • Heintz A.P.
        • Odicino F.
        • Maisonneuve P.
        • et al.
        Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.
        Int J Gynaecol Obstet. 2006; 95: S161-S192
        • Erzen M.
        • Rakar S.
        • Klancnik B.
        • Syrjänen K.
        Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study.
        Gynecol Oncol. 2001; 83: 100-108
        • Ishibashi H.
        • Takano M.
        • Miyamoto M.
        • et al.
        Role of endometriosis as a prognostic factor for post-progression survival in ovarian clear cell carcinoma.
        Mol Clin Oncol. 2017; 7: 1027-1031
        • Lu J.
        • Tao X.
        • Zhou J.
        • et al.
        Improved clinical outcomes of patients with ovarian carcinoma arising in endometriosis.
        Oncotarget. 2017; 8: 5843-5852
        • Kim H.S.
        • Kim T.H.
        • Chung H.H.
        • Song Y.S.
        Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis.
        Br J Cancer. 2014; 110: 1878-1890
        • Ren T.
        • Wang S.
        • Sun J.
        • et al.
        Endometriosis is the independent prognostic factor for survival in Chinese patients with epithelial ovarian carcinoma.
        J Ovarian Res. 2017; 10: 67
        • Bai H.
        • Cao D.
        • Yuan F.
        • et al.
        Prognostic value of endometriosis in patients with stage I ovarian clear cell carcinoma: experiences at three academic institutions.
        Gynecol Oncol. 2016; 143: 526-531
        • Shafrir A.L.
        • Babic A.
        • Tamimi R.M.
        • Rosner B.A.
        • Tworoger S.S.
        • Terry K.L.
        Reproductive and hormonal factors in relation to survival and platinum resistance among ovarian cancer cases.
        Br J Cancer. 2016; 115: 1391-1399
        • Dinkelspiel H.E.
        • Matrai C.
        • Pauk S.
        • et al.
        Does the presence of endometriosis affect prognosis of ovarian cancer?.
        Cancer Invest. 2016; 34: 148-154
        • Li Q.
        • Sun Y.
        • Zhang X.
        • et al.
        Endometriosis-associated ovarian cancer is a single entity with distinct clinicopathological characteristics.
        Cancer Biol Ther. 2019; 20: 1029-1034
        • Bounous V.E.
        • Ferrero A.
        • Fuso L.
        • et al.
        Endometriosis-associated ovarian cancer: a distinct clinical entity?.
        Anticancer Res. 2016; 36: 3445-3449
        • Riccio L.D.G.C.
        • Santulli P.
        • Marcellin L.
        • Abrão M.S.
        • Batteux F.
        • Chapron C.
        Immunology of endometriosis.
        Best Pract Res Clin Obstet Gynaecol. 2018; 50: 39-49
        • Zhang L.
        • Conejo-Garcia J.R.
        • Katsaros D.
        • et al.
        Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
        N Engl J Med. 2003; 348: 203-213
        • Curiel T.J.
        • Coukos G.
        • Zou L.
        • et al.
        Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
        Nat Med. 2004; 10: 942-949
        • Cabasag C.J.
        • Arnold M.
        • Butler J.
        • et al.
        The influence of birth cohort and calendar period on global trends in ovarian cancer incidence.
        Int J Cancer. 2020; 146: 749-758
        • Wong A.S.
        • Leung P.C.
        Role of endocrine and growth factors on the ovarian surface epithelium.
        J Obstet Gynaecol Res. 2007; 33: 3-16
        • Jatoi A.
        • Foster N.R.
        • Kalli K.R.
        • et al.
        Prior oral contraceptive use in ovarian cancer patients: assessing associations with overall and progression-free survival.
        BMC Cancer. 2015; 15: 711
        • Munksgaard P.S.
        • Blaakaer J.
        The association between endometriosis and gynecological cancers and breast cancer: a review of epidemiological data.
        Gynecol Oncol. 2011; 123: 157-163
        • Scott R.B.
        Malignant changes in endometriosis.
        Obstet Gynecol. 1953; 2: 283-289
        • Eisenberg V.H.
        • Weil C.
        • Chodick G.
        • Shalev V.
        Epidemiology of endometriosis: a large population-based database study from a healthcare provider with 2 million members.
        BJOG. 2018; 125: 55-62
        • Missmer S.A.
        • Hankinson S.E.
        • Spiegelman D.
        • Barbieri R.L.
        • Marshall L.M.
        • Hunter D.J.
        Incidence of laparoscopically confirmed endometriosis by demographic, anthropometric, and lifestyle factors.
        Am J Epidemiol. 2004; 160: 784-796